Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SUTRO BIOPHARMA, INC.STRO · Entity 5797 | Chief Business Officer | July 08, 2025 | August 26, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SUTRO BIOPHARMA, INC.
Report date July 08, 2025 · Filed August 26, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,056 |
Ending reported balance
After 2025-07-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-07-08 · Exercise / conversion · Acquired 25,000 · Balance 25,000 Row 2 · 2025-07-08 · Tax withholding · Disposed 8,944 · Balance 16,056 F1: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. |
| Restricted Stock Units (RSUs)SEC Table II · derivative / convertible security · Expires 2028-07-08 | Direct | 75,000 |
Reported balance
After 2025-07-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-07-08 · Exercise / conversion · Disposed 25,000 · Balance 75,000 F2: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F3: The RSUs vest as to 1/4th of the total award annually beginning on July 8, 2025, subject to the reporting person's continued service to the Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person.
F2: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.
F3: The RSUs vest as to 1/4th of the total award annually beginning on July 8, 2025, subject to the reporting person's continued service to the Issuer through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 08, 2025 Filed Aug 26, 2025 21:21 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Units (RSUs) · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-023084 · form4-08272025_010822.xml · derivative · entry 3 Leyman Barbara · CIK 0002028309 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 25,000 shares Expires 2028-07-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total award annually beginning on July 8, 2025, subject to the reporting person's continued service to the Issuer through each vesting date. Read SEC document |
| July 08, 2025 Filed Aug 26, 2025 21:21 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 8,944 | $0.78 | $6,976.32 |
DisclosureSEC source: 0001415889-25-023084 · form4-08272025_010822.xml · nonDerivative · entry 2 Leyman Barbara · CIK 0002028309 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,056 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. Read SEC document |
| July 08, 2025 Filed Aug 26, 2025 21:21 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-023084 · form4-08272025_010822.xml · nonDerivative · entry 1 Leyman Barbara · CIK 0002028309 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 04, 2025 Filed Apr 8, 2025 16:09 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Units (RSUs) · Derivative | 84,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-010383 · form4-04082025_080432.xml · derivative · entry 2 Leyman Barbara · CIK 0002028309 · Chief Business Dev. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,500 Underlying: Common Stock · 84,500 shares Expires 2029-03-02 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total award annually beginning on March 2, 2026, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| April 04, 2025 Filed Apr 8, 2025 16:09 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (Right to Buy) · Derivative | 91,000 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0001415889-25-010383 · form4-04082025_080432.xml · derivative · entry 1 Leyman Barbara · CIK 0002028309 · Chief Business Dev. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,000 Underlying: Common Stock · 91,000 shares Expires 2035-04-04 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total award monthly, beginning on May 4, 2025, with 100% of the award being vested and exercisable on April 4, 2029, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| July 08, 2024 Filed Jul 10, 2024 16:11 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Units (RSUs) · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-019462 · form4-07102024_080725.xml · derivative · entry 2 Leyman Barbara · CIK 0002028309 · Chief Business Dev. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-07-08 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total award annually beginning on July 8, 2025, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| July 08, 2024 Filed Jul 10, 2024 16:11 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (Right to Buy Common Stock) · Derivative | 125,000 | $0.00 Strike: $3.04 | $0.00 |
DisclosureSEC source: 0001415889-24-019462 · form4-07102024_080725.xml · derivative · entry 1 Leyman Barbara · CIK 0002028309 · Chief Business Dev. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2034-07-08 F1 · derivative.exercise_date: The option vests as to 25% of the total award on July 8, 2025, then in equal monthly installments over the following three years, subject to the reporting person's continued service to the issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.